1. A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) Authors: Sauter, C.S.; Matasar, M.J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M.L.; Portlock, C.S.; Straus, D.J.; Zelenetz, A.D.; McCall, S.S.; Miller, S.T.; Courtien, A.I.; Younes, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPACTS ON IMMUNE EVASIVE MECHANISMS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – A SINGLE CENTER EXPERIENCE. (12th June 2019) Authors: Sauter, C.S.; Lin, R.J.; Ho, C.; Devlin, S.M.; Maloy, M.A.; Perales, M.; Dahi, P.B.; Schoder, H.; Jakubowski, A.A.; Barker, J.N.; Papadopoulos, E.B.; Giralt, S.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA. (June 2017) Authors: Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; Moskowitz, A.; Zelenetz, A.; Ahsanuddin, S.; Callan, D.; Freidin, B.; Porzio, R.; Soiffer, J.; Copeland, A.; Dang, T.; Rademaker, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO-1583: Non-invasive radiomic imaging prediction of tumour hypoxia: biomarker for FLASH irradiation?. (November 2020) Authors: Sanduleanu, S.; Tamanupadhaya@gmail.com, T.; Klaassen, R.; Woodruff, H.; Hatt, M.; Kaanders, J.; Vrieze, O.; Laarhoven, H.; Subramiam, R.; Huang, S.H.; Bratman, S.; Dubois, L.; Miclea, R.; Di Perri, D.; Geets, X.; Crispin-Ortuzar, M.; Aptea, A.; Hun Oh, J.; Lee, N.; Humm, J. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL. (June 2017) Authors: Scott, D.W.; Li, H.; Harvey, Y.; Chan, F.; Mottok, A.; Boyle, M.; Evens, A.M.; Schoder, H.; Straus, D.J.; Bartlett, N.L.; Sweetenham, J.W.; Barr, P.M.; Fanale, M.A.; Hsi, E.D.; Cook, J.R.; Kahl, B.S.; Leonard, J.P.; Friedberg, J.W.; Leblanc, M.; Steidl, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗